Results 61 to 70 of about 55,917 (264)

Deciphering the Mechanisms of Statin-Ezetimibe Drug Combinations Using Boolean Logical Modeling and Transcriptomic Data. [PDF]

CPT Pharmacometrics Syst Pharmacol
ABSTRACT Drug Combinations offer increased therapeutic efficacy and reduced toxicity compared with single agents. Understanding a drug combination's mechanisms of action (MoA) can provide important insights into therapeutic efficacy. The MoA of many FDA‐approved drugs, however, often remains unclear.
Wang RS, Pedrelli M, Ahmed O, Paolo G, Parini P, Loscalzo J.   +5 more
europepmc   +2 more sources

Dispensing of actionable pharmacogenetic drugs among adults receiving cardiovascular disease medications in the Northern Netherlands: A serial cross‐sectional study

Clinical Pharmacology &Therapeutics, EarlyView.
The extent of pharmacogenetic (PGx) drug dispensing among Dutch adults receiving medications for cardiovascular disease (CVD) is unknown. Using the University of Groningen IADB.nl pharmacy database, we performed a serial cross‐sectional study (2019–2023) to estimate the annual prevalence of PGx drug dispensing and annual rates of initiation.
Zhuolin Zhang, Guiling Zhou, Jens H. J. Bos, Eelko Hak, Talitha Feenstra, Frank Klont   +5 more
wiley   +1 more source

Statin use and risk of remote seizure after first new onset status epilepticus

Epilepsia, EarlyView.
Abstract Objective Preclinical evidence supports the role of statins as antiepileptogenic agents. In this study, we investigated the risk of remote unprovoked seizures (RS) according to the use of statin therapy in a cohort of first‐ever status epilepticus (SE) survivors. Methods Retrospective analysis was made of adult patients (age ≥ 14 years) with a
Niccolò Orlandi, Giada Giovannini, Lisa Taruffi, Margherita Burani, Jefe Laureine Ngnintedem Dontsop, Mara Malerba, Simona Scolastico, Laura Madrassi, Leonardo Affronte, Matteo Pugnaghi, Anna Elisabetta Vaudano, Simona Lattanzi, Stefano Meletti   +12 more
wiley   +1 more source

Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity

Journal of Lipid Research, 1998
The effects of atorvastatin on the expression of the hepatic HMG-CoA reductase and LDL receptor genes were investigated in rats. Like the other statins, atorvastatin increased the rate of degradation and presumably cycling of the hepatic LDL receptor. In
Gene C. Ness, Christopher M. Chambers, Dayami Lopez   +2 more
doaj   +1 more source

Solid dispersions of atorvastatin with Kolliphor RH40: enhanced supersaturation and improvement in a hyperlipidemic rat model

, 2023
Atorvastatin is a potent lipid-lowering drug with poor solubility and high presystemic clearance that limits its therapeutic efficacy. The aim of this study was to develop solid dispersions and micellar systems to obtain fastdissolving atorvastatin ...
Guarnizo Herrero, Victor, Peña Fernández, M. Ángeles, Torrado-Santiago, Santiago, Torrado Salmerón, Carlos Félix, Torre Iglesias, Paloma Marina De La, de la Torre-Iglesias, Paloma Marina, Torrado Durán, Guillermo, Peña, M. Ángeles, Guarnizo-Herrero, Víctor, Torrado Durán, Santiago, Torrado-Salmerón, Carlos, Torrado, Guillermo   +11 more
core   +1 more source

Atorvastatin versus tetrahydrolipstatin in male patients with dyslipidemia: A systematic review and meta-analysis [PDF]

Journal of Pharmacy & Pharmacognosy Research
Context: Atorvastatin is typically used in the treatment of dyslipidemia. However, the interest in using anti-obesity medications such as orlistat has grown rapidly as obesity is one of the variables associated with dyslipidemia.
Nur Aini Hasan, Viskasari Pintoko Kalanjati, Kusuma Eko Purwantari, Abdurachman Abdurachman, Muhammad Miftahussurur   +4 more
doaj   +1 more source

Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer

International Journal of Cancer, EarlyView.
ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue, Daniele Carchidi, Philipp Schmucker, Roland Seiler, Bernhard Kiss, Catarina Macedo‐Silva, Marianna Kruithof‐de Julio   +6 more
wiley   +1 more source

Fenofibrate ameliorated atorvastatin and piperine-induced ROS mediated reproductive toxicity in male Wistar rats

Toxicology Reports
Atorvastatin and fenofibrate are well-known lipid-lowering drugs. Atorvastatin acts by reducing the production of cholesterol through the inhibition of the 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG Co-A reductase) enzyme, whereas fenofibrate ...
Sanjib Ghosh, Sweata Sarkar, Maharaj Biswas   +2 more
doaj   +1 more source

EFFICACY AND SAFETY OF THERAPY WITH ATORVASTATIN IN HIGH DOSES

Рациональная фармакотерапия в кардиологии, 2016
Large epidemiological trails shown that hypercholesterolemia is one of the main risk factor of ischemic heart disease (IHD). Correction of the hypercholesterolemia with GmGKoA reductase inhibitors (statins) essentially reduces IHD morbidity and mortality.
A. N. Meshkov
doaj   +1 more source

Research Progress of Berberine in Kidney Disease: Targeting Mitochondria and Ferroptosis

iNew Medicine, EarlyView.
This figure illustrates the model‐specific renoprotective mechanisms of berberine (BBR) across three major kidney diseases. From left to right, the diagram shows that BBR targets distinct core pathways depending on the pathological context: in diabetic nephropathy (DN), BBR activates AMPK to improve mitochondrial energy metabolism; in acute kidney ...
Liuqing Wang, Rongyu Guo, Xiaojun Feng, Liqin Tang   +3 more
wiley   +1 more source